Navigation Links
Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
Date:1/22/2013

CARLSBAD, Calif., Jan. 22, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced its acquisition of BAC BV, a privately held company based in the Netherlands, and a leader in the discovery, development and manufacture of protein purification products. The acquisition expands Life's capabilities and product offerings in the growing market of biopharmaceutical research and manufacturing.

"Our acquisition of BAC BV positions Life Technologies as a leading provider of end-to-end solutions that are widely utilized in the bioprocess workflow," said Tony Hunt , head of BioProduction at Life Technologies. "Combining BAC's current portfolio and pipeline with our pre-existing portfolio expands Life's product offering and enables us to compete more fully across the protein purification market. We intend to immediately integrate the portfolios and leverage the Life commercial platform to drive accelerated growth in this market."

Bioprocessing is the production and analytical testing of biologically-based therapeutics, which are developed in cultured cells or microorganisms, and include drugs, vaccines, biosimilars, and gene and cell therapies. Life Technologies' Gibco® brand is the market leader in cell culture media, a position it has held for 50 years, and the company more recently integrated its POROS® brand of chromatography resins for purification of therapeutic products into the Bioproduction portfolio.

The acquisition expands Life's existing portfolio by adding BAC BV's unique set of innovative and proprietary affinity ligands to the company's world-class POROS® resin
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neptune Technologies & Bioressources Inc. To Contact The Firm
2. Statement by Life Technologies Board of Directors
3. Brain State Technologies to Host Open House and Demonstrate Their Revolutionary Technology
4. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
6. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
8. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
11. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... NAMUR , Belgium , Nov. 24, ... life sciences company focused on developing diagnostic tests for cancer ... lung cancer study will be presented at the Science for ... Louvain-la-Neuve, Belgium . The data come from ... collected at the Pneumology department of the Centre Hospitalier Universitaire ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Aug. 22 DNA2.0,Inc. (http://www.DNA20.com ), ... and,Operon Biotechnologies (http://www.operon.com ), a leader ... a partnership to utilize their,synergistic technologies and ... production platform with DNA2.0,s,gene synthesis process, the ...
... 21 ,Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... (SAR) of a class of,internally-developed compounds that ... the company as potential treatments for irritable ... is currently,under evaluation in a Phase 1b ...
... Under Fire, WORCESTER, Mass., Aug. 21 ... proud to announced that Dr.,Robert Lanza, the company,s ... recognized for his research and contributions to stem,cell ... PharmaVOICE (cover,story July/August issue). Dr. Lanza is one ...
Cached Biology Technology:Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... alarming invasion of round goby into Great Lakes tributaries: ... A team of scientists from the University of Toronto, ... of Guelph has identified a drastic invasion of round ... of the Thames, Sydenham, Ausable and Grand Rivers. A ...
... awarded through federal stimulus research funding, a Kansas State ... eventually help diabetics preserve their eyesight. Dolores Takemoto, ... from the National Eye Institute to study how a ... protein kinase C gamma, called PKC gamma, and how ...
... , , , WALL, N.J., Aug. ... will be holding its second quarter conference call, which will be broadcast ... Eastern Time. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ... International, Inc. Second Quarter 2009 Conference Call, When: ...
Cached Biology News:BIO-key(R) Announces Second Quarter Conference Call Schedule 2
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: